2
ALL2
Dren BioYear
2
ALL1
20221
2020DEALS // DEV.
2
ALL2
DealsCountry
2
ALL2
U.S.A2
ALL1
Pfizer Inc1
Taiho VenturesTherapeutic Area
2
ALL2
OncologyStudy Phase
2
ALL1
Discovery1
UndisclosedDeal Type
2
ALL1
Collaboration1
Series A FinancingProduct Type
2
ALL2
Large moleculeDosage Form
0
ALLLead Product
2
ALL1
Bispecific Antibody1
DR-01Target
0
ALLLead Product(s) : Bispecific Antibody
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Pfizer Inc
Deal Size : $1,025.0 million
Deal Type : Collaboration
Details : The strategic collaboration will focus on the discovery and development of therapeutic bispecific antibodies for selected oncology targets using Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $25.0 million
January 11, 2022
Lead Product(s) : Bispecific Antibody
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Pfizer Inc
Deal Size : $1,025.0 million
Deal Type : Collaboration
Lead Product(s) : DR-01
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Taiho Ventures
Deal Size : $60.0 million
Deal Type : Series A Financing
Dren Bio Announces a $60M Series A Financing
Details : Dren will utilize the proceeds to advance its two lead programs through early clinical development. Dren’s first program, DR-01, is an antibody-based therapy to treat rare leukemias and lymphomas as well as specific phenotypes of auto-immune disorders.
Brand Name : DR-01
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 16, 2020
Lead Product(s) : DR-01
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Taiho Ventures
Deal Size : $60.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?